MX2018003713A - Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente). - Google Patents

Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente).

Info

Publication number
MX2018003713A
MX2018003713A MX2018003713A MX2018003713A MX2018003713A MX 2018003713 A MX2018003713 A MX 2018003713A MX 2018003713 A MX2018003713 A MX 2018003713A MX 2018003713 A MX2018003713 A MX 2018003713A MX 2018003713 A MX2018003713 A MX 2018003713A
Authority
MX
Mexico
Prior art keywords
post
treating
traumatic headache
reducing
persistent
Prior art date
Application number
MX2018003713A
Other languages
English (en)
Inventor
Bigal Marcelo
Original Assignee
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals Int Gmbh filed Critical Teva Pharmaceuticals Int Gmbh
Publication of MX2018003713A publication Critical patent/MX2018003713A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

En este documento se describen métodos para tratar o reducir la incidencia de dolor de cabeza postraumático y/o al menos un síntoma secundario asociado con dolor de cabeza postraumático en un sujeto que comprende administrar al sujeto un anticuerpo monoclonal que modula la ruta de CGRP; también se proporcionan composiciones para usarse en los métodos descritos; también se describen el anticuerpo antagonista G1 y los anticuerpos derivados de G1 dirigidos a CGRP.
MX2018003713A 2015-09-24 2016-09-23 Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente). MX2018003713A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562232343P 2015-09-24 2015-09-24
US201662375825P 2016-08-16 2016-08-16
PCT/IB2016/055720 WO2017051385A1 (en) 2015-09-24 2016-09-23 Preventing, treating, and reducing (persistent) post-traumatic headache

Publications (1)

Publication Number Publication Date
MX2018003713A true MX2018003713A (es) 2018-08-15

Family

ID=57121460

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003713A MX2018003713A (es) 2015-09-24 2016-09-23 Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente).

Country Status (13)

Country Link
US (3) US20170088612A1 (es)
EP (1) EP3353202B1 (es)
JP (2) JP2018532728A (es)
KR (2) KR20180058777A (es)
CN (1) CN108473560A (es)
AU (2) AU2016325738A1 (es)
CA (1) CA2999809A1 (es)
EA (1) EA201890578A1 (es)
ES (1) ES2846878T3 (es)
HK (2) HK1258474A1 (es)
IL (1) IL258008A (es)
MX (1) MX2018003713A (es)
WO (1) WO2017051385A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3495392T1 (sl) 2011-05-20 2021-11-30 H. Lundbeck A/S Sestavki proti CGRP in uporaba le-teh
CN107827982B (zh) 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
AU2015214502B2 (en) 2014-02-05 2019-06-06 Merck Sharp & Dohme Llc Tablet formulation for CGRP-active compounds
UA123759C2 (uk) 2014-03-21 2021-06-02 Тева Фармасьютікалз Інтернешнл Гмбх Застосування моноклонального антитіла, яке інгібує шлях пов'язаного з геном кальциноніну пептиду (cgrp), для лікування або зниження частоти випадків мігренозного головного болю у суб'єкта
US10392434B2 (en) 2016-09-23 2019-08-27 Teva Pharmaceuticals International Gmbh Treating refractory migraine
US20190225689A1 (en) * 2018-01-22 2019-07-25 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-pd-1 antibodies
US10899826B1 (en) 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
AU2020206241A1 (en) * 2019-01-08 2021-08-26 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies
US20200383983A1 (en) * 2019-04-18 2020-12-10 Allergan Sales, Llc Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo
MX2022015230A (es) * 2020-06-03 2023-01-04 Miotox Llc Metodos y usos zonal y dirigido para el tratamiento de un trastorno de migra?a.
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704770D0 (sv) * 1997-12-19 1997-12-19 Astra Ab New use
ES2433251T5 (es) * 2005-11-14 2020-03-13 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos
SI3495392T1 (sl) * 2011-05-20 2021-11-30 H. Lundbeck A/S Sestavki proti CGRP in uporaba le-teh
MX2014008456A (es) * 2012-01-10 2014-11-25 Noxxon Pharma Ag Acidos nucleicos que enlazan especificamente a cgrp.
US8722060B2 (en) * 2012-05-23 2014-05-13 William J. Binder Method of treating vertigo

Also Published As

Publication number Publication date
AU2016325738A1 (en) 2018-04-12
US20200148761A1 (en) 2020-05-14
KR20200035163A (ko) 2020-04-01
IL258008A (en) 2018-06-28
EA201890578A1 (ru) 2018-12-28
CA2999809A1 (en) 2017-03-30
KR20180058777A (ko) 2018-06-01
HK1258385A1 (zh) 2019-11-08
US20170088612A1 (en) 2017-03-30
WO2017051385A1 (en) 2017-03-30
US20220048986A1 (en) 2022-02-17
EP3353202B1 (en) 2020-11-04
HK1258474A1 (zh) 2019-11-15
JP2018532728A (ja) 2018-11-08
EP3353202A1 (en) 2018-08-01
AU2019261726A1 (en) 2019-11-28
ES2846878T3 (es) 2021-07-30
JP2020002172A (ja) 2020-01-09
CN108473560A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
MX2019003337A (es) Tratamiento para migraña refractaria.
MX2018003713A (es) Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente).
MX2019003338A (es) Tratamiento de cefalea en racimos.
MY195110A (en) Antibodies to PD-1 and uses Thereof
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
MX2022002364A (es) Anticuerpos anti-pd-l1.
PH12016501976A1 (en) Antibodies, pharmaceutical compositions and uses thereof
MX2020001272A (es) Anticuerpos dirigidos contra interleucina-33 (il-33).
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
MX2020012816A (es) Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
SG10201900571YA (en) Anti-pd-1 antibodies
CA2886433C (en) Human monoclonal anti-pd-l1 antibodies and methods of use
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
CR20190576A (es) Anticuerpos biespecíficos inhibidores de punto de control
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
MY195443A (en) Tissue Factor Pathway Inhibitor Antibodies and uses Thereof
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
WO2018009507A8 (en) COMBINATION OF A TIM -4 ANTAGONIST AND METHODS OF USE
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
EA201990576A1 (ru) Лечение рефрактерной мигрени
AR106143A1 (es) Prevención, tratamiento y reducción de cefaleas postraumáticas (persistentes)
WO2018174408A8 (ko) 항-dr5 항체 및 그의 용도